You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    PROJECT SUMMARY The family of Filoviridae consisting of five ebolaviruses and two marburgviruses are causative agents of severe hemorrhagic fever with human case fatality rates ofTheepidemic of Ebola virus disease in West Africa was unprecedented both in geographic scope and size and highlighted the extent of the threat filoviruses could pose to global public health and the urgent need for develop ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Scanning Chlamydia proteome for vaccine antigens

    SBC: ImmPORT Therapeutics Inc dba Antigen Discovery Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Throughout the World Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen. In areas with poor sanitary conditions C. trachomatis causes trachoma the most common cause of preventable blindness in the World. In symptomatic cases, unless therapy is implemented in a timely manner, long-term sequelae including, pelvic inflammatory disease ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Urine Diagnostics for Aspergillosis

    SBC: PEARL DIAGNOSTICS, INC.            Topic: NIAID

    Invasive aspergillosisIAcontinues to cause morbidity and death in medically immune compromised patientslargely because we lack sensitive diagnostic tests that are easy to use during high risk periodsWe discovered that fungal galactofuranose containing antigens are excreted in urine of infected animals and peopleusing a novel monoclonal antibodymAbIn a phase I STTRwe engineered a lateral flow devic ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Microfluidic CAR-T Cell Processing Device

    SBC: GPB Scientific, Inc.            Topic: 101

    ABSTRACT The goal of this Fast-Track STTR project is to develop a Deterministic Lateral Displacement (DLD) microfluidic device that can enrich white blood cells (WBCs) from a typical leukapheresis unit in 1 hr, for use in manufacturing cancer cellular immunotherapy. Chimeric antigen receptor T cell (CAR-T) therapy has been recommended for FDA approval to treat relapsed or refractory pediatric and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Online Training For Addressing Perinatal Depression

    SBC: PRAXIS, INC.            Topic: 104

    Project Summary The primary goal of this proposal is to develop, implement, and evaluate an online module to improve obstetric providers’ knowledge, attitudes, and practices regarding perinatal mood and anxiety disorders. Upwards of 1 in 5 women suffer from perinatal mood and anxiety disorders. Left untreated, they have deleterious effects on maternal and birth outcomes, infant attachment, and c ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Mitochondrial Antioxidant Neurodegenerative Therapeutics: XJB-5-131 Derivatives

    SBC: SOLANO PHARMACEUTICALS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Oxidative damage to mitochondrial is a major source of toxicity in diseases such as Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD). Mitochondria are energy powerhouses of the cell, and decline in their function by oxidative damage is a common feature among neurodegenerative diseases. Despite years of effort, however, generic ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. DNA HELICASE AND PRIMASE INHIBITORS FOR BIODEFENSE

    SBC: MICROBIOTIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The increasing prevalence of antibiotic-resistant strains of bacterial pathogens represents a major unmet medical need. Naturally occuring or intentionally engineered drug-resistance in biothreat agents is also a serious risk for biodefense. The development of new antibiotics against unexploited targets with novel mechanisms of action is a vital part of the sol ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Type 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Prospective/Retrospective Motion Correction System for Motion Robust Pediatric MR

    SBC: ROBIN MEDICAL INC            Topic: NIMH

    DESCRIPTION (provided by applicant): The long term objective of the project is to develop a new motion robust magnetic resonance imaging (MRI) technology. Magnetic resonance imaging is a powerful tool that aids in the diagnosis of individual subjects, guides their clinical care, ad provides insights into the mechanisms of normal and atypical development. The characterization of mental health disor ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government